杰美特 reported revenue of ¥0.31B for the period ended 2026-06-30, +5.2% year on year. Net income was ¥-0.01B, a -4.2% net margin on a 27.7% gross margin. The largest revenue line is 智能手机保护类产品 at 55% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.31B | +5.2% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 27.7% | Net margin -4.2% |
| Revenue Q/Q | +17.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 智能手机保护类产品 | ¥0.17B | 55.1% |
| 其他产品 | ¥0.10B | 31.8% |
| 超硬涂层精密刀具 | ¥0.03B | 8.7% |
| 平板电脑保护类产品 | ¥0.01B | 3.9% |
| 光电功能材料 | ¥0.00B | 0.4% |
| 其他精密产品 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.22B | 72.3% |
| R&D | ¥0.02B | 8.1% |
| SG&A | ¥0.07B | 22.8% |
| Tax & other | ¥0.00B | 0.0% |
| Item | Amount |
|---|---|
| Total assets | ¥2.51B |
| Total liabilities | ¥0.95B |
| Shareholders' equity | ¥1.56B |
| Equity / assets | 62.3% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | 548% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
康泰医学 ・ 欧陆通 ・ 回盛生物 ・ 天阳科技 ・ 海晨股份 ・ 捷强装备 ・ 蒙泰高新 ・ 金春股份 ・ 维康药业 ・ 大叶股份 ・ 迦南智能 ・ 盛德鑫泰
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies